CD8A and neoplasm: Moreover, based on the coculture of dLNs with 4T1 tumor cells to determine the abundance of functional 4T1-specific CTLs, TheraVacM and TheraVacplus treatment also resulted in the generation of higher levels of functional 4T1-specific CD8+ T cells (CD8+CD107a+) in dLNs (Figure 6A–C) compared to the control/PBS treatment.